title: Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward.
abstract: The development of new immunosuppressive drugs has slowed markedly over the past several years, and the outlook that improved therapy will be available to the next generation of transplant recipients is bleak. In this viewpoint, the authors outline some of important barriers to new drug development and suggest specific steps that the transplant community can take to overcome them.
authors.affiliation: Departments of Surgery and Immunology, von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
authors.forename: M D
authors.initials: MD
authors.lastname: Stegall
authors.affiliation: Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA.
authors.forename: R E
authors.initials: RE
authors.lastname: Morris
authors.affiliation: Department of Medicine, University of Cincinnati School of Medicine, Cincinnati, OH.
authors.forename: R R
authors.initials: RR
authors.lastname: Alloway
authors.affiliation: Departments of Medicine and Surgery, Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL.
authors.forename: R B
authors.initials: RB
authors.lastname: Mannon
mesh_terms: D055808:Drug Discovery; D006084:Graft Rejection / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016377:Organ Transplantation; D011379:Prognosis; D066027:Transplant Recipients
chemical_list: D007166:Immunosuppressive Agents
keywords: editorial/personal viewpoint; ethics and public policy Discipline